About Sinocare
Sinocare Inc. is a Chinese medical technology company specialising in diabetes management and chronic disease monitoring. Established in 2002 and headquartered in Changsha, Hunan Province, China, the firm develops, manufactures, and markets blood glucose monitoring systems, continuous glucose monitoring (CGM) devices, blood pressure monitors, uric acid meters, cholesterol testing systems, and other rapid diagnostic products. Sinocare ranks among the world’s largest manufacturers of blood glucose monitoring devices and describes itself as “The Leading Diabetes Digital Management Expert in the World.”1
History
Sinocare was founded in 2002 with the mission of making blood glucose monitoring more affordable and accessible for people with diabetes in China. The company initially focused on developing home-use blood glucose meters and testing strips.
Over the subsequent years, Sinocare expanded its research and manufacturing capabilities, becoming one of China’s leading providers of diabetes monitoring products. It was also recognised as China’s first publicly listed blood glucose meter company.
A significant milestone occurred in 2016 when Sinocare acquired Trividia Health Inc. (formerly Nipro Diagnostics Inc.) and PTS Diagnostics Inc. in the United States. These acquisitions substantially expanded the company’s international presence and strengthened its position within the global diagnostics industry.
Business Overview
Sinocare operates as a high-tech healthcare company focused on:
- Diabetes management
- Chronic disease monitoring
- Point-of-care diagnostic testing
- Digital healthcare solutions
- Biosensing technology
The company integrates medical devices with digital platforms to support long-term disease management for both patients and healthcare professionals. Its digital ecosystem combines biosensors, Internet of Things (IoT) technologies, smart healthcare services, and health management applications.2
Products
Sinocare manufactures a comprehensive range of healthcare devices, including:
Blood Glucose Monitoring
- Blood glucose meters
- Blood glucose test strips
- Lancets and lancing devices
- Control solutions
Continuous Glucose Monitoring (CGM)
- Wearable CGM sensors
- Mobile monitoring applications
- Real-time glucose tracking systems
Blood Pressure Monitoring
- Automatic upper-arm blood pressure monitors
- Home blood pressure management devices
Multiparameter Testing
- Uric acid meters
- Cholesterol testing systems
- Haemoglobin testing products
- Ketone testing products
Hospital and Professional Diagnostics
- Point-of-care diagnostic analysers
- Clinical laboratory testing systems
- Professional diabetes management solutions3
Global Presence
According to corporate data, Sinocare maintains:
- 9 global research and manufacturing sites
- Product availability in 187 countries and regions
- More than 25 million users worldwide
- Status as the No. 1 blood glucose monitoring brand in China
- A ranking among the top four blood glucose monitoring companies globally based on reported market position
Research and Innovation
Sinocare invests significantly in biosensor technology and chronic disease management. Its research priorities include:
- Continuous glucose monitoring
- Biosensing technologies
- Artificial intelligence for diabetes management
- Smart healthcare platforms
- Remote patient monitoring
The company holds more than 780 authorised patents according to its official disclosures.
Mission and Vision
Mission
Guided by love, with a commitment to global access and health outcomes, Sinocare delivers innovative, high-quality solutions for people living with diabetes and related chronic diseases.
Vision
To become the Leading Diabetes Digital Management Expert in the World.
Its stated core values emphasise commitment to customers, employees, partners, society, and shareholders.
Markets
Sinocare serves diverse customer groups, including:
- Individuals managing diabetes at home
- Hospitals and clinics
- Healthcare professionals
- Pharmacies
- Public health organisations
Its products are distributed throughout Asia, Europe, North America, South America, the Middle East, and Africa.
Recent Developments
Sinocare continues to expand its digital healthcare portfolio, particularly in continuous glucose monitoring (CGM). The company has introduced new CGM technologies featuring extended sensor wear, AI-assisted glucose analytics, and integrated mobile health applications, whilst also showcasing broader digital health solutions at major international medical exhibitions.
Summary
Sinocare has evolved from a domestic Chinese blood glucose meter manufacturer into an international medical technology company focused on diabetes and chronic disease management. Its portfolio spans traditional blood glucose meters, wearable CGM systems, blood pressure monitors, diagnostic analysers, and digital healthcare platforms. Through sustained investment in biosensing technology and international expansion, the company has established a presence in more than 180 countries and serves millions of users worldwide.
